Vincent Rizzo: Beta Blocker Choice May Impact Portal Vein Thrombosis and Survival in Cirrhosis
Vincent Rizzo, Chief Department of Internal Medicine at Icahn School of Medicine at Mount Sinai, shared a post on LinkedIn about a recent article he and his colleagues co- authored, published in Liver International, adding:
“Latest article, just published yesterday in Liver International. large study, over 8,000 patients with potentially practice changing, meanin agful results. big, huge shoutout to the team!!!
here is the lay summary:
In patients with liver cirrhosis, beta-blockers are commonly used to reduce complications related to high blood pressure in the liver.
In this large real-world study, we found that one commonly used beta-blocker (propranolol) was associated with a higher risk of blood clots in the portal vein, while another (carvedilol) did not increase this risk and was linked to better survival.
These findings suggest that the choice of beta-blocker may significantly affect patient outcomes.”
Title: Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study
Authors: Hazem Abosheaishaa, Khaled Elfert, Mohammed Abusuliman, Abdellatif Ismail, Abdullah Olimy, Ahmed Elsayed Alzamzamy, Ahmed Omran, Vincent Rizzo, Mahmoud Nassar, Mohamed El-Kassas
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question